{"type":"trials","record":{"id":39569,"source_id":"clinicaltrials-gov","external_id":"NCT04141059","title":"Effect of Oligopin® on Skin Ageing","brief_summary":"Extrinsic or exogenous ageing is caused by repetitive exposure of the skin to harmful agents, while primary cause the exposure to ultraviolet (UV) radiation, known as photoageing, including solar effect. Chronic solar UV exposure has multiple damaging effects on skin, such as wrinkling, dryness, dyspigmentation, epidermal thinning and increasing fragility. In addition, solar exposure and age increase a subepidermal band. Fibrillar collagen, which is synthesized from fibroblasts, is the predominant extracellular matrix (ECM) component of the dermis. Collagen type I and III are considered to be the major interstitial, fiber forming collagen in normal human dermis. In addition, the dermis contains collagen types IV (gelatine), V and VI. Other important component of the EMC of the dermis are elastic fibers being elastin (ELN) their main component and play a critical role in skin elasticity and the reduction of elastic fiber production results in impaired elasticity. UV radiation induces ECM degeneration and consequently an increase in fragility and loss of elasticity of the skin. This process is mediated by an increase in matrix metalloproteinases (MMPs) expression in human skin which are responsible for degrading ECM proteins, such as collagen, fibronectin and elastin. The natural inhibitors of MMPs are tissue inhibitors of metalloproteinases (TIMPs), being TIMP-1 the most relevant TIMP affecting collagen metabolism.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Technological Centre of Nutrition and Health, Spain","enrollment":74,"countries":["Spain"],"start_date":"2019-11-19","completion_date":"2020-09-10","last_update_date":"2022-03-02","source_url":"https://clinicaltrials.gov/study/NCT04141059","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:19.060264+00:00","last_seen_at":"2026-09-25T06:20:14.553+00:00","metadata":{"sex":"ALL","acronym":"OLIGOSKIN","age_range":"35 Years","comparator":"Placebo","organization":"Technological Centre of Nutrition and Health, Spain","interventions":["Oligopin","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in skin elasticity — At weeks 2, 3 and 4","Change in skin wrinkles — At weeks 2, 3 and 4","Change in skin hydratation — At weeks 2, 3 and 4","Change in skin spots — At weeks 2, 3 and 4","Change in subepidermal low-echogenic band — At weeks 2, 3 and 4","Change in biomarkers of collagen and elastin dynamics in serum — At weeks 2 and 4","Change in expression levels of genes related to collagen synthesis and degradation in PBMCs — At weeks 2 and 4","Oligopin® long-term blood metabolites characterization — At weeks 2 and 4","Transcriptomics in PBMCs — At weeks 2 and 4","Metabolomics in serum — At weeks 2 and 4","Postprandial Oligopin® blood metabolites characterization — At week 1","Capacity of Oligopin® blood metabolites to modulate collagen levels — At week 1","Capacity of Oligopin® blood metabolites to modulate secreted collagen type I — At week 1","Capacity of Oligopin® blood metabolites to modulate secreted collagen type III — At week 1","Capacity of Oligopin® blood metabolites to modulate pyruvate target genes — At week 1","Capacity of Oligopin® blood metabolites to modulate MMP-1 activity — At week 1","Capacity of Oligopin® blood metabolites to modulate TIMP-1 levels — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-1 activity — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-2 activity — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-9 activity — At week 1"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","source_has_results":false},"controlled_terms":["Skin Aging","Oligopin","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: skin ageing.","quality_checked_at":"2026-09-25T06:20:17.523592+00:00","duplicate_cluster_key":"id:nct04141059","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-11-19 to 2020-09-10","comparator":"Placebo","confidence":"structured-source","population":"ALL · 35 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:14.591Z","intervention":["Oligopin","Placebo"],"participants":74,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in skin elasticity — At weeks 2, 3 and 4","Change in skin wrinkles — At weeks 2, 3 and 4","Change in skin hydratation — At weeks 2, 3 and 4","Change in skin spots — At weeks 2, 3 and 4","Change in subepidermal low-echogenic band — At weeks 2, 3 and 4","Change in biomarkers of collagen and elastin dynamics in serum — At weeks 2 and 4","Change in expression levels of genes related to collagen synthesis and degradation in PBMCs — At weeks 2 and 4","Oligopin® long-term blood metabolites characterization — At weeks 2 and 4","Transcriptomics in PBMCs — At weeks 2 and 4","Metabolomics in serum — At weeks 2 and 4","Postprandial Oligopin® blood metabolites characterization — At week 1","Capacity of Oligopin® blood metabolites to modulate collagen levels — At week 1","Capacity of Oligopin® blood metabolites to modulate secreted collagen type I — At week 1","Capacity of Oligopin® blood metabolites to modulate secreted collagen type III — At week 1","Capacity of Oligopin® blood metabolites to modulate pyruvate target genes — At week 1","Capacity of Oligopin® blood metabolites to modulate MMP-1 activity — At week 1","Capacity of Oligopin® blood metabolites to modulate TIMP-1 levels — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-1 activity — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-2 activity — At week 1","Capacity of Oligopin® blood metabolites to inhibit MMP-9 activity — At week 1"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"skin-aging","is_published":true,"match_reasons":["Title contains controlled term: skin ageing.","Abstract contains controlled term: photoageing.","Source terminology contains: skin aging.","Title supplies longevity context: ageing.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Skin ageing","slug":"skin-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/39569","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}